Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatic Insufficiency
Open-data reference.
15 US clinical trials · 3 currently recruiting
Active & Recent Trials
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
X4 Pharmaceuticals
NCT06858696
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
Boehringer Ingelheim
NCT06957756
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
Eli Lilly and Company
NCT07401862
Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency
Axcella Health
NCT04147936
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
Eli Lilly and Company
NCT06719128
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
Bristol-Myers Squibb
NCT00859053
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
Eli Lilly and Company
NCT05916560
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
Debiopharm International
NCT01860326
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function
Novartis
NCT00416702
A Study of Tirzepatide in Participants With Impaired Liver Function
Eli Lilly and Company
NCT03940742
A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
Eli Lilly and Company
NCT01836185
The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)
Merck Sharp & Dohme
NCT01797536
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
Eli Lilly and Company
NCT05440344
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
Pfizer
NCT00645021
A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT01186588
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 14 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Hepatic Insufficiency Trial Landscape
ClinicalTrials.gov lists 15 US studies indexed under Hepatic Insufficiency, and 3 of those are currently open to recruitment — roughly 20% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Hepatic Insufficiency shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 14 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Hepatic Insufficiency is led by Eli Lilly and Company with 6 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 15 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Hepatic Insufficiency?
PlainTrial tracks 15 US clinical trials for Hepatic Insufficiency, of which 3 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Hepatic Insufficiency?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.